Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

NCT03625401 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease, Early Onset

Interventions

DRUG: AD-35 60mg group
DRUG: Placebo group

Sponsor

Zhejiang Hisun Pharmaceutical Co. Ltd.

Collaborators

[object Object]